Vaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. grew its position in Vaxcyte, Inc. (NASDAQ:PCVX) by 15.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 74,907 shares of the company’s stock after acquiring an additional 10,243 shares during the period. Harbor Capital Advisors Inc. owned about 0.06% of Vaxcyte worth $6,132,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Riverview Trust Co purchased a new stake in Vaxcyte in the 3rd quarter valued at approximately $27,000. Blue Trust Inc. lifted its holdings in shares of Vaxcyte by 33.5% in the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after buying an additional 93 shares during the period. Meeder Asset Management Inc. boosted its stake in shares of Vaxcyte by 1,007.9% in the third quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock valued at $80,000 after buying an additional 635 shares in the last quarter. Nomura Asset Management Co. Ltd. acquired a new position in Vaxcyte during the third quarter worth $92,000. Finally, Quest Partners LLC acquired a new position in Vaxcyte during the second quarter worth $70,000. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a research report on Wednesday, November 6th. The Goldman Sachs Group assumed coverage on shares of Vaxcyte in a report on Friday, December 20th. They set a “buy” rating and a $135.00 price objective on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and set a $140.00 price target on shares of Vaxcyte in a research report on Wednesday, November 6th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $145.71.

Insider Buying and Selling

In other news, CEO Grant Pickering sold 15,000 shares of Vaxcyte stock in a transaction on Friday, November 1st. The stock was sold at an average price of $106.82, for a total value of $1,602,300.00. Following the completion of the sale, the chief executive officer now owns 435,219 shares of the company’s stock, valued at $46,490,093.58. The trade was a 3.33 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew Guggenhime sold 42,000 shares of the stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $115.39, for a total value of $4,846,380.00. Following the transaction, the chief financial officer now owns 90,383 shares in the company, valued at $10,429,294.37. This trade represents a 31.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 113,732 shares of company stock worth $11,730,787. 3.10% of the stock is owned by corporate insiders.

Vaxcyte Price Performance

PCVX stock opened at $81.08 on Friday. The company’s 50 day simple moving average is $90.20 and its 200-day simple moving average is $93.26. Vaxcyte, Inc. has a 12 month low of $58.10 and a 12 month high of $121.06. The firm has a market capitalization of $10.11 billion, a PE ratio of -17.63 and a beta of 0.98.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($1.10) by $0.27. During the same period in the previous year, the company posted ($0.91) EPS. As a group, sell-side analysts anticipate that Vaxcyte, Inc. will post -4.14 earnings per share for the current year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.